Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTANOL versus SULFADIAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTANOL versus SULFADIAZINE.
AZO GANTANOL vs SULFADIAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Competitive inhibitor of dihydropteroate synthase, blocking the synthesis of folic acid in bacteria.
AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.
Oral: 2-4 g initially, then 1 g every 4-6 hours for mild to moderate infections; for severe infections, 4 g initially followed by 1.5 g every 4 hours. IV: Not available in IV form in the US; if using oral suspension, adjust accordingly.
None Documented
None Documented
Clinical Note
moderateSulfadiazine + Gatifloxacin
"Sulfadiazine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfadiazine + Rosoxacin
"Sulfadiazine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfadiazine + Levofloxacin
"Sulfadiazine may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSulfadiazine + Trovafloxacin
"Sulfadiazine may increase the hypoglycemic activities of Trovafloxacin."
Sulfamethoxazole terminal half-life: 9-12 hours in adults with normal renal function (CrCl >80 mL/min); prolonged to 20-50 hours in CKD (CrCl <30 mL/min); phenazopyridine half-life: 9-11 hours
Terminal elimination half-life 10-20 hours (prolonged in renal impairment; may require dose adjustment)
Renal: 70% as sulfamethoxazole (30% acetylated), N5-acetylated metabolite accounts for 15%; fecal: 20% of dose excreted unchanged in bile; biliary: minor contribution (<5%)
Renal excretion of unchanged drug (50-70%) and acetylated metabolites; minor biliary/fecal (<5%)
Category C
Category D/X
Sulfonamide Antibiotic
Sulfonamide Antibiotic